drugset / Trial / NCT05223088
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
Timeline
- Start
- 2021-10-31
- Primary completion
- 2023-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Tegafur | Unknown | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |